Mushrooms and TNF-Alpha: The Anti-Inflammatory Evidence

Mushrooms & Cytokine Modulation

3 compound classes

Reishi triterpenes, cordycepin from Cordyceps, and oyster mushroom polysaccharides each suppress TNF-alpha through distinct molecular pathways. A 2026 systematic review and meta-analysis confirmed Ganoderma triterpenes as the most thoroughly studied class.

Pozzobon et al., Pharmaceuticals, 2026

NF-κB

the master inflammatory transcription factor that all three mushroom compound classes independently target to suppress TNF-alpha production

Human PBMCs

ganoderic acid C1 suppressed TNF-alpha production in peripheral blood mononuclear cells from asthma patients, not just mouse macrophages (Liu et al., 2015)

Arthritis model

Antcin K from Antrodia inhibited TNF-α, IL-1β, and IL-8 in synovial fibroblasts and reduced cartilage degradation (Achudhan et al., 2021)

Pozzobon et al., Pharmaceuticals, 2026

View as image ↗

TNF-alpha blockers, biologic drugs like adalimumab (Humira) and etanercept, are among the top-selling pharmaceuticals on earth. They work by neutralizing a single cytokine: tumor necrosis factor-alpha (TNF-alpha), the molecule that coordinates much of the inflammatory damage in rheumatoid arthritis, Crohn's disease, and other chronic conditions.

The premise is simple: block TNF-alpha, reduce inflammation. Multiple mushroom compounds appear to work toward the same target, through different molecular mechanisms, without the immune suppression risks that accompany biologic therapies.

TNF-alpha (tumor necrosis factor-alpha) is a cytokine produced primarily by macrophages in response to infection or injury. It coordinates the inflammatory response by signaling other immune cells, driving fever, and promoting the destruction of infected or malignant tissue. When TNF-alpha production becomes chronically dysregulated, it drives tissue damage in autoimmune conditions. Multiple mushroom compounds suppress TNF-alpha by blocking activation of NF-κB, the transcription factor that triggers TNF-alpha production in macrophages.

For the broader picture of how mushrooms target NF-κB and other inflammatory pathways, see How Mushrooms Fight Inflammation: NF-κB, COX-2, and Beyond.

What TNF-Alpha Does: When It Helps and When It Becomes a Problem

TNF-alpha starts as a useful protein. When macrophages detect a pathogen, they produce TNF-alpha as one of the first alarm signals. It recruits neutrophils to the infection site, activates other immune cells, and promotes the destruction of infected cells. Without it, the body would struggle to contain bacterial infections.

The problem arises when TNF-alpha production becomes chronically elevated. In rheumatoid arthritis, persistently high TNF-alpha drives the synovial inflammation that erodes cartilage and bone. In Crohn's disease, it sustains intestinal inflammation that doesn't resolve between flares. In metabolic syndrome, elevated TNF-alpha contributes to insulin resistance and low-grade systemic inflammation.

TNF-alpha doesn't act alone. It triggers its own production through a feedback loop involving NF-κB, a transcription factor that lives in most cells. When macrophages receive an inflammatory signal, NF-κB moves into the nucleus and activates genes for TNF-alpha, IL-6, IL-1β, and other pro-inflammatory cytokines. Blocking NF-κB activation is therefore one of the primary mechanisms by which compounds reduce TNF-alpha levels.

Guggenheim and colleagues, in a 2014 review of immune modulation from five major mushrooms in an oncology context (Agaricus blazei, Cordyceps, maitake, reishi, and turkey tail), documented that cytokine modulation is a consistent feature across medicinal mushroom species.^[7]

Reishi Triterpenes: The Most-Studied Mushroom TNF-Alpha Suppressors

Reishi (Ganoderma lucidum) contains the most extensively studied anti-inflammatory compounds in the mushroom research literature. The active compounds are triterpenes, steroid-like molecules found in the mushroom's fruiting body and extracted in hot water or alcohol preparations.

Dudhgaonkar and colleagues tested reishi triterpenes in 2009 in both cell culture and an animal model. In LPS-stimulated macrophages, reishi triterpenes markedly suppressed both TNF-alpha and IL-6 secretion. In endotoxemic mice (a model of acute systemic inflammation), the same triterpenes suppressed TNF-alpha and IL-6 in vivo.^[1] The combination of in vitro and in vivo data from a single study is relatively unusual and strengthens the mechanistic case.

A 2026 systematic review and meta-analysis by Pozzobon and colleagues synthesized the full preclinical evidence base for Ganoderma lucidum triterpenes as anti-inflammatory agents.^[2] This is the highest-level summary of reishi triterpene anti-inflammatory activity available. As a meta-analysis of preclinical data, it confirms the consistency of the effect across studies, though it does not substitute for human clinical trial evidence (which remains limited).

The primary mechanism: reishi triterpenes inhibit NF-κB activation in macrophages. This reduces transcription of TNF-alpha and IL-6 at the gene level rather than simply mopping up cytokines that have already been released. Inhibiting NF-κB is also how the pharmaceutical biologic drugs work at a higher level of specificity; the mushroom compounds appear to act earlier in the same pathway.

For the specific triterpene compounds responsible and how they compare to one another, the companion article Mushroom Triterpenes and TNF-Alpha Suppression: Quantifying Anti-Inflammatory Potency provides a compound-by-compound breakdown.

Ganoderic Acid C1: When the Data Gets Specific

Among the individual reishi triterpenes, ganoderic acid C1 has unusually direct evidence for TNF-alpha suppression in human-relevant cells.

Liu and colleagues in 2015 tested ganoderic acid C1 (isolated from ASHMI, a standardized reishi-containing formula) against TNF-alpha production in two systems: mouse macrophages in culture, and peripheral blood mononuclear cells (PBMCs) taken from human asthma patients.^[3]

The distinction between macrophage cell culture and human PBMCs matters. Most mechanistic studies use rodent macrophage cell lines (RAW 264.7 is the most common) stimulated with LPS to simulate infection. Human PBMC data comes from actual human blood cells, which includes monocytes, T cells, and B cells in the proportions they exist in a living person. The two systems can behave differently.

Ganoderic acid C1 suppressed TNF-alpha production in both systems. This doesn't confirm the same effect would occur in a clinical trial of reishi supplementation, but it closes one gap in the translation chain between "works in mouse cells" and "relevant to humans."

The asthma patient population is also notable. These were not healthy volunteers but people with a condition characterized by cytokine-driven inflammation. The fact that ganoderic acid C1 suppressed TNF-alpha in cells isolated from people with active inflammatory disease is a more stringent test than healthy cells at baseline.

Cordycepin: A Separate Molecular Path to the Same Target

Reishi triterpenes are not the only mushroom-derived compounds documented to suppress TNF-alpha. Cordycepin, a compound from Cordyceps fungi, reaches the same target through a different molecular route.

Kim and colleagues in 2006 showed that cordycepin inhibited LPS-induced inflammation in macrophages by suppressing NF-κB activation, but through Akt kinase and p38 kinase pathways rather than through the direct NF-κB inhibition characteristic of triterpenes.^[4] Akt and p38 are upstream signaling proteins that feed into NF-κB activation: blocking them at this earlier stage prevents NF-κB from being activated in the first place.

Cordycepin is structurally an adenosine analog, a molecule that resembles adenosine (a natural cellular signaling molecule) and interferes with certain adenosine-dependent processes. This makes it chemically distinct from polysaccharides and from steroidal triterpenes. The fact that a third compound class, with a completely different structure and mechanism, also suppresses TNF-alpha via NF-κB is notable: it suggests the pathway itself is a reliable anti-inflammatory target accessible through multiple molecular entry points.

The practical limitation: most cordycepin research uses cultured macrophage cells. Human pharmacokinetic data on whether oral cordycepin reaches macrophages in the tissue concentrations used in these experiments is sparse.

Oyster Mushrooms and Antrodia: TNF-Alpha Suppression Beyond Exotic Species

The research above involves reishi (Ganoderma lucidum) and Cordyceps, neither of which is a common dietary mushroom. Two studies extend the TNF-alpha suppression evidence to more accessible species.

Jedinak and colleagues in 2011 tested an extract of oyster mushroom (Pleurotus ostreatus) in LPS-stimulated macrophages.^[5] Oyster mushroom extract inhibited both NF-κB and AP-1 signaling. AP-1 (activator protein 1) is a separate transcription factor that also drives TNF-alpha and IL-6 expression. The Dudhgaonkar reishi triterpene study reported AP-1 inhibition as well, so a dual NF-κB/AP-1 block is not unique to oyster mushroom, but the oyster data documents it in a common, inexpensive edible species. Targeting both NF-κB and AP-1 simultaneously produces broader suppression of the pro-inflammatory gene program than blocking either pathway alone.

Oyster mushrooms are inexpensive, available in most grocery stores, and consumed globally as a food. The preclinical macrophage data doesn't confirm that eating oyster mushrooms has anti-inflammatory effects in humans, but it shows the compound responsible for the effect in cell culture is present in a widely accessible species.

Achudhan and colleagues in 2021 tested antcin K, a triterpene from Antrodia cinnamomea (a mushroom used in Taiwanese traditional medicine), in a more clinically specific model: synovial fibroblasts from patients with rheumatoid arthritis.^[6] Antcin K specifically inhibited TNF-alpha, IL-1β, and IL-8 expression in these cells and reduced cartilage degradation markers. Using cells from the actual tissue affected by rheumatoid arthritis, rather than a generic macrophage cell line, is a closer approximation of clinical relevance, though it still falls short of a clinical trial.

The antcin K study also illustrates a broader pattern: multiple species outside the reishi/Cordyceps pair contain triterpenes with anti-inflammatory properties, and each tends to have a slightly different cytokine inhibition profile.

For how these mechanisms compare to polysaccharide-based anti-inflammatory effects, see Triterpenes vs. Polysaccharides: Different Anti-Inflammatory Pathways.

What Drives TNF-Alpha Suppression: A Pattern Across Species

Looking across all seven studies, a structural pattern emerges.

Every entry in this table suppresses TNF-alpha, and all routes lead back to NF-κB as the central target, whether blocking it directly (triterpenes), through upstream kinases (cordycepin), or by targeting an additional transcription factor alongside it (oyster mushroom AP-1 inhibition).

This convergence on a single pathway suggests NF-κB inhibition is the primary mechanism by which structurally diverse mushroom compounds reduce TNF-alpha. It also means the effects are likely additive or overlapping rather than representing truly independent mechanisms.

Mechanism · Five Compounds, One Target

All Roads Lead to NF-κB

Structurally unrelated mushroom compounds enter the inflammatory signaling chain at different points, yet each one ends at the same NF-κB switch that controls TNF-alpha production. The convergence is what makes the target credible.

Reishi triterpene extract

Ganoderma lucidum

Direct at NF-κB

Triterpenes act on the NF-κB switch itself and also blunt AP-1, cutting TNF-alpha and IL-6 in macrophages and in endotoxemic mice.

Cell + animalRef 1

Ganoderic acid C1

Ganoderma lucidum

Direct at NF-κB

A single isolated triterpene that suppressed TNF-alpha in mouse macrophages and in human PBMCs from asthma patients.

Human cellsRef 3

Cordycepin

Cordyceps

Upstream at Akt / p38

An adenosine analog that blocks the Akt and p38 kinases sitting above NF-κB, stopping the signal before it reaches the switch.

Cell cultureRef 4

Oyster mushroom extract

Pleurotus ostreatus

Dual: NF-κB + AP-1

A common edible species whose extract blocks NF-κB and the independent AP-1 factor at once, closing two routes to TNF-alpha.

Cell cultureRef 5

Antcin K

Antrodia cinnamomea

NF-κB pathway

A triterpene tested in synovial fibroblasts from rheumatoid arthritis patients, suppressing TNF-alpha, IL-1β, and IL-8.

RA cell modelRef 6

NF-κB activation blocked

The transcription factor stays out of the nucleus, so the TNF-alpha gene is never switched on

Reduced TNF-alpha production

Less of the master cytokine that coordinates chronic inflammatory tissue damage

Every route shown is preclinical — cell culture, animal, or human-cell models. None of these studies is a clinical trial of oral mushroom supplementation, and the step from cell-level suppression to measurable benefit in people is not yet established.

Source: Dudhgaonkar et al. (2009); Liu et al. (2015); Kim et al. (2006); Jedinak et al. (2011); Achudhan et al. (2021)

Guggenheim and colleagues' 2014 cross-species review reinforces this picture: cytokine modulation is a recurring feature across Agaricus blazei, Cordyceps, maitake, reishi, and turkey tail, making it one of the most conserved themes in medicinal mushroom pharmacology.^[7]

The Translation Problem: How Far This Evidence Goes

The majority of the research reviewed here uses a standard macrophage activation model: LPS-stimulated mouse macrophage cell lines, then measuring cytokine output. This is the workhorse of innate immunology research because it is highly reproducible and controlled. But it has limitations.

LPS stimulation produces inflammatory responses far more acute than most chronic disease contexts. The concentrations of mushroom compounds used in cell culture are often much higher than what reaches macrophages after oral supplementation in a human. And rodent macrophage cell lines (RAW 264.7 is the most common) can differ from primary human macrophages in their signaling responses.

The Liu 2015 ganoderic acid C1 study is the closest to bridging this gap, testing in actual human blood cells, but it is still not a controlled trial of reishi supplementation in people with inflammatory disease.

What would be needed for clinical conclusions: randomized controlled trials measuring serum TNF-alpha before and after mushroom supplementation in people with TNF-alpha-mediated conditions like rheumatoid arthritis or Crohn's disease. These trials exist for specific reishi products in adjacent conditions (the Pozzobon meta-analysis covers preclinical data, not human trials), but they are not yet available in sufficient number or quality to make strong clinical claims.

Evidence Review

1. Cell culture (macrophages)completed

   Reishi triterpenes, cordycepin, oyster mushroom extract, and antcin K each suppress TNF-alpha in LPS-stimulated macrophage models (Dudhgaonkar 2009; Kim 2006; Jedinak 2011; Achudhan 2021).

2. Animal modelcompleted

   Reishi triterpenes suppressed TNF-alpha and IL-6 in LPS-induced endotoxemic mice, adding in vivo confirmation (Dudhgaonkar 2009).

3. Human cells (ex vivo)current

   Ganoderic acid C1 suppressed TNF-alpha in peripheral blood mononuclear cells from human asthma patients, the closest step to human relevance so far (Liu 2015).

4. Randomized controlled trialmissing

   No adequately powered RCT has measured serum TNF-alpha before and after mushroom supplementation in people with TNF-alpha-mediated disease.

The mechanistic evidence is strong and consistent from cell culture through animal models and into human blood cells, but the final step, a controlled trial in people, has not been taken. That gap is why these findings establish plausibility, not proven clinical benefit.

Dudhgaonkar et al. (2009); Kim et al. (2006); Jedinak et al. (2011); Liu et al. (2015); Achudhan et al. (2021)

The evidence establishes biological plausibility: multiple mushroom compounds reduce TNF-alpha production in macrophage models through documented pathways. It does not yet establish clinical efficacy in humans.

For a broader look at which cytokines mushrooms modulate and how the balance between pro- and anti-inflammatory effects works, see How Mushrooms Balance Pro- and Anti-Inflammatory Cytokines, Mushroom Compounds and IL-6 Reduction, and The Cytokine Storm: Can Mushrooms Help Modulate Immune Overreaction?.

Not Medical Advice

Moderate

Mushroom compounds are not a substitute for TNF-alpha biologics

Concern

The TNF-alpha suppression described here comes from cell and animal studies, not from clinical trials in people. Stopping or replacing a prescribed biologic (such as adalimumab or etanercept) with mushroom supplements in an attempt to control rheumatoid arthritis, Crohn's disease, or another autoimmune condition risks uncontrolled inflammation and disease flares.

What the research says

Treat mushrooms as a food and a research topic, not a therapy. Any change to treatment for a TNF-alpha-mediated condition should be made with the prescribing physician, not on the basis of preclinical mechanism data.

Particularly relevant for: People with rheumatoid arthritis, Crohn's disease, or other autoimmune conditions, and anyone taking immunomodulating medication

What to do

Discuss any mushroom supplement with your clinician before adding it, especially alongside a biologic or other immune-modulating drug.

Editorial safety note; based on the preclinical evidence base reviewed in this article

The Bottom Line

Reishi triterpenes, cordycepin from Cordyceps, and oyster mushroom polysaccharides each suppress TNF-alpha in macrophage models by targeting NF-κB and related inflammatory transcription factors. A 2026 meta-analysis by Pozzobon and colleagues represents the highest-quality summary of the preclinical reishi data, and ganoderic acid C1 has been tested in human peripheral blood cells from asthma patients. The evidence base establishes biological plausibility for TNF-alpha suppression across multiple mushroom species, but clinical trial data in humans with TNF-alpha-mediated conditions remains limited.

Frequently Asked Questions

What is TNF-alpha and why is it dangerous?

TNF-alpha (tumor necrosis factor-alpha) is a cytokine produced by macrophages that coordinates inflammation during infection and injury. In normal amounts, it is essential for immune defense. When chronically elevated, it drives the tissue-destroying inflammation seen in rheumatoid arthritis (eroding cartilage), Crohn's disease (sustaining intestinal inflammation), and metabolic syndrome (contributing to insulin resistance). Biologic drugs that specifically block TNF-alpha are among the most prescribed medications for autoimmune conditions.

Which mushrooms reduce TNF-alpha?

Reishi (Ganoderma lucidum) has the most evidence, with multiple studies on its triterpenes including a 2026 systematic review and meta-analysis by Pozzobon and colleagues. Cordyceps has evidence through cordycepin's NF-κB/Akt/p38 mechanism (Kim et al., 2006). Oyster mushroom (Pleurotus ostreatus) suppressed TNF-alpha in macrophages by blocking both NF-κB and AP-1 (Jedinak et al., 2011). Antrodia cinnamomea, through its compound antcin K, showed suppression in rheumatoid arthritis cell models (Achudhan et al., 2021).

How do mushrooms inhibit inflammatory signals?

Most mushroom compounds reduce TNF-alpha by blocking NF-κB, the transcription factor that activates TNF-alpha gene expression in macrophages. Different compound classes reach NF-κB through different upstream routes: reishi triterpenes inhibit NF-κB directly; cordycepin blocks upstream Akt and p38 kinases before they activate NF-κB; oyster mushroom polysaccharides inhibit both NF-κB and a secondary transcription factor, AP-1, simultaneously. All routes produce the same downstream result: reduced TNF-alpha and IL-6 output from stimulated macrophages.

What natural compounds block TNF-alpha?

Among mushroom compounds, reishi triterpenes (particularly ganoderic acids), cordycepin from Cordyceps, oyster mushroom polysaccharides, and antcin K from Antrodia have all shown TNF-alpha suppression in laboratory models. Other natural compounds studied for TNF-alpha inhibition include curcumin, resveratrol, and omega-3 fatty acids. The mechanistic data for mushroom compounds is well-established at the cell culture level, though human clinical evidence for TNF-alpha reduction from mushroom supplementation remains limited.

Do medicinal mushrooms work as anti-inflammatory agents?

In cell culture and animal models, yes: multiple mushroom compounds reduce pro-inflammatory cytokines including TNF-alpha and IL-6 through NF-κB pathway inhibition, and this finding is consistent across reishi, Cordyceps, oyster mushroom, and Antrodia. The 2026 Pozzobon meta-analysis is the highest-quality summary of this preclinical evidence for reishi. Whether this translates to meaningful clinical anti-inflammatory effects from oral mushroom supplementation in humans has not been established in adequately powered randomized trials.

Sources & References

1. 1RTHM-00152·Dudhgaonkar, Shailesh et al. (2009). “Suppression of the inflammatory response by triterpenes isolated from the mushroom Ganoderma lucidum..” International immunopharmacology.Study breakdown →PubMed →↩
2. 2RTHM-02241·Pozzobon, Rafaela Guedes et al. (2026). “Anti-Inflammatory Potential of Ganoderma lucidum Triterpenes: A Systematic Review and Meta-Analysis of Preclinical Evidence..” Pharmaceuticals (Basel.Study breakdown →PubMed →↩
3. 3RTHM-00720·Liu, Changda et al. (2015). “Ganoderic acid C1 isolated from the anti-asthma formula, ASHMI™ suppresses TNF-α production by mouse macrophages and peripheral blood mononuclear cells from asthma patients..” International immunopharmacology.Study breakdown →PubMed →↩
4. 4RTHM-00103·Kim, Ho Gyoung et al. (2006). “Cordycepin inhibits lipopolysaccharide-induced inflammation by the suppression of NF-kappaB through Akt and p38 inhibition in RAW 264.7 macrophage cells..” European journal of pharmacology.Study breakdown →PubMed →↩
5. 5RTHM-00219·Jedinak, Andrej et al. (2011). “Anti-inflammatory activity of edible oyster mushroom is mediated through the inhibition of NF-κB and AP-1 signaling..” Nutrition journal.Study breakdown →PubMed →↩
6. 6RTHM-00670·Achudhan, David et al. (2021). “Antcin K Inhibits TNF-α, IL-1β and IL-8 Expression in Synovial Fibroblasts and Ameliorates Cartilage Degradation: Implications for the Treatment of Rheumatoid Arthritis..” Frontiers in immunology.Study breakdown →PubMed →↩
7. 7RTHM-00323·Guggenheim, Alena G et al. (2014). “Immune Modulation From Five Major Mushrooms: Application to Integrative Oncology..” Integrative medicine (Encinitas.Study breakdown →PubMed →↩